^
    Back
    Association details:
    Biomarker:SLFN11 elevation
    Cancer:Hepatocellular Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Gastroenterology
    Title:

    Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti-PD-1 therapy efficacy in hepatocellular carcinoma

    Published date:
    02/14/2023
    Excerpt:
    ICIs were more effective in HCC patients with high serum SLFN11 levels.
    DOI:
    10.1053/j.gastro.2023.02.005